Neuroscience technology for better brain health

Cambridge Cognition Holdings plc (AIM: COG) is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health.

INVESTORS
SHARE PRICE
SHAREHOLDERS
ANNOUNCEMENTS
Reports & accounts
BOARD OF DIRECTORS
COMPANY INFORMATION
Corporate Governance​
Registrar
INVESTOR ALERTS
For over 30 years, our software has been at the forefront of digital brain health, supporting clients internationally from renowned research institutions and healthcare providers to leading pharmaceutical and biotechnology companies.

Today Cambridge Cognition has developed a sustainable business, positioned for growth, built upon unparalleled scientific heritage and digital health technology innovation.

Highlights from the Capital
Markets Showcase

Highlights from the Capital
Markets Showcase

Play Video
  • Introducing the science and technology showcase | Matthew Stork, Chief Executive Officer   
  • Taking trials from lab to living room | Rob Baker, Head of Product   
  • Digital biomarkers are here and now | Francesca Cormack, Chief Scientist & Liam Kaufman, VP Corporate Business Development   
  • OK Computer! AI in clinical trials | Nick Taptiklis, Head of R&D Technology  
  • Introducing the science and technology showcase | Matthew Stork, Chief Executive Officer   
  • Taking trials from lab to living room | Rob Baker, Head of Product   
  • Digital biomarkers are here and now | Francesca Cormack, Chief Scientist & Liam Kaufman, VP Corporate Business Development   
  • OK Computer! AI in clinical trials | Nick Taptiklis, Head of R&D Technology  

“Disorders of the brain, such as Alzheimer’s disease, Schizophrenia, Parkinson’s, depression and mental illness are the world’s primary cause of ill health, resulting in higher costs and more hospitalisations than any other disease group.”

World Health Organisation

Company highlights

Cambridge Cognition’s proprietary technologies include the world’s most validated cognitive assessment software, CANTAB®, recognised as an international gold standard and accepted both academically and commercially through thousands of peer-reviewed publications

Cambridge Cognition has a solid history of financial performance enabling the company to self-fund R&D projects and commercialisation opportunities

Cambridge Cognition software technologies serve a number of high value growth markets, including pharmaceutical clinical trials, academic and medical research, and digital health.

Cambridge Cognition counts clients in over 100 countries, including the world’s top 20 pharmaceutical companies and over 800 academic research institutions.

Our mission is to build a highly valuable business improving brain health worldwide with scientifically proven digital health technologies to enable better research, detection, treatment and prevention.

Dr Steven Powell
Chairman, Cambridge Cognition

The information contained within this section of the website is for the purposes of AIM Rule 26 and was last reviewed 1 March 2024.

Cambridge Cognition
Scroll to Top